LOS ANGELES, Calif., June 18, 2026
TORL BioTherapeutics has reported encouraging preliminary Phase 1 clinical data for its investigational Claudin 6-targeting antibody-drug conjugate (ADC) ixotatug vedotin (Ixo-V; TORL-1-23) in combination with bevacizumab for the treatment of recurrent ovarian cancer. The findings, presented at the ESMO Gynaecological Cancers Congress 2026, demonstrated promising antitumor activity and a manageable safety profile in patients with Claudin 6-positive (CLDN6+) ovarian cancer, a population with limited treatment options and poor long-term outcomes. The combination achieved a notable objective response rate (ORR) of 32.1% and an impressive disease control rate (DCR) of 92.9% across all treated participants, highlighting its potential as a new therapeutic strategy in both platinum-resistant and platinum-sensitive disease settings. The results further strengthen TORL’s development program for ixotatug vedotin as the company advances toward pivotal clinical milestones anticipated in 2027.
ADC Combination Demonstrates Encouraging Clinical Activity
The preliminary data were generated from an ongoing first-in-human Phase 1 dose-escalation study evaluating the safety, efficacy, and antitumor activity of ixotatug vedotin combined with bevacizumab in patients with recurrent ovarian cancer expressing Claudin 6. A total of 29 patients received treatment, with many having undergone multiple prior therapies, including platinum-based chemotherapy, taxanes, bevacizumab, PARP inhibitors, and other targeted agents. According to RECIST v1.1 criteria, the combination produced an overall response rate of 32.1%, while disease control was achieved in nearly all treated patients.
Response rates remained consistent across dosing cohorts, and clinical activity was observed even among patients previously exposed to bevacizumab, PARP inhibitors, and mirvetuximab soravtansine. These findings suggest that ixotatug vedotin may provide meaningful therapeutic benefit in heavily pretreated ovarian cancer populations where treatment resistance frequently limits available options.
Favorable Safety Profile Supports Further Development
Advertisement
Beyond efficacy, investigators reported a favorable tolerability profile for the combination therapy. No clinically significant bleeding events, ocular toxicities, bowel perforations, or thromboembolic complications were observed during the study period. The manageable safety profile is particularly important in recurrent ovarian cancer, where treatment-related toxicities often impact patient quality of life and limit long-term therapy.
Researchers believe the encouraging balance between efficacy and tolerability may support broader clinical development of the regimen in earlier treatment settings. The data also reinforce the potential value of targeting Claudin 6, an oncofetal protein that is highly expressed in several malignancies but largely absent in healthy adult tissues, making it an attractive target for precision oncology approaches and next-generation ADC therapies.
CATALINA Program Advances Toward Registrational Milestones
The positive results provide additional momentum for TORL’s broader ovarian cancer development strategy. The company is currently advancing CATALINA-2, a global randomized Phase 2 registrational study evaluating ixotatug vedotin in women with CLDN6-positive platinum-resistant ovarian cancer, with pivotal topline results expected in mid-2027. In parallel, the CATALINA-4 study is exploring the therapy in combination with chemotherapy in newly diagnosed advanced ovarian cancer patients prior to surgery. Beyond ovarian cancer, TORL continues to investigate ixotatug vedotin in additional solid tumor indications, including non-small cell lung cancer.
The investigational ADC has already received Fast Track Designation from the U.S. Food and Drug Administration, reflecting its potential to address significant unmet medical needs. As interest in targeted oncology therapies continues to grow, the latest ESMO data position ixotatug vedotin as a promising candidate in the evolving landscape of precision cancer medicine, offering hope for improved outcomes among patients with difficult-to-treat ovarian cancers.
Source: TORL BioTherapeutics press release
